Effective #anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque #erosion (the EROSION study)

http://m.eurheartj.oxfordjournals.org/content/early/2016/08/26/eurheartj.ehw381

Conclusion For patients with ACS caused by plaque erosion, conservative treatment with anti-thrombotic therapy without stenting may be an option.

Randomized trial of switching from prescribed non-selective non-steroidal #anti-inflammatory drugs to prescribed #celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)

http://m.eurheartj.oxfordjournals.org/content/early/2016/10/02/eurheartj.ehw387.article-info

Interpretation In subjects 60 years and over, free from CV disease and taking prescribed chronic nsNSAIDs, CV events were infrequent and similar on celecoxib and nsNSAIDs. There was no advantage of a strategy of switching prescribed nsNSAIDs to prescribed celecoxib. This study excluded an increased risk of the primary endpoint of more than two events per 1000 patient-years associated with switching to prescribed celecoxib.

Effects of #anti-TNF-α treatment on #lipid profile in rheumatic diseases: an analytical cohort study

http://arthritis-research.biomedcentral.com/articles/10.1186/s13075-016-1148-1

TNF-α inhibitor treatment was associated with a significant increase in TC and TG levels and the AI. Adding statins to the treatment was associated with a significant decrease in LDL levels.

Non-steroidal #anti-inflammatory drug use is associated with increased risk of out-of-hospital #cardiac arrest: a nationwide case–time–control study
https://academic.oup.com/ehjcvp/article/3/2/100/2739709/Non-steroidal-anti-inflammatory-drug-use-is

Use of diclofenac (odds ratio [OR], 1.50 [95% confidence interval (CI) 1.23–1.82]) and ibuprofen [OR, 1.31 (95% CI 1.14–1.51)] was associated with a significantly increased risk of OHCA. Use of naproxen [OR, 1.29 (95% CI 0.77–2.16)], celecoxib [OR, 1.13 (95% CI 0.74–1.70)], and rofecoxib (OR, 1.28 [95% CI 0.74–1.70)] was not significantly associated with increased risk of OHCA; however, these groups were characterized by few events. Use of non-selective NSAIDs was associated with an increased early risk of OHCA. The result was driven by an increased risk of OHCA in ibuprofen and diclofenac users.

out-of-hospital cardiac arrest (OHCA)

!!
Efficacy and safety of #anti-inflammatory agents for the treatment of major #depressive disorder: a systematic review and meta-analysis of randomised controlled trials

..Four studies explored the antidepressant effects of NSAIDs in addition to traditional antidepressants. In all four studies, celecoxib was added at the same dose (400 mg/day). Traditional antidepressants used were sertraline, fluoxetine and reboxetine.

We combined these studies for a subgroup meta-analysis, finding that antidepressants combined with celecoxib were better than antidepressants alone, leading to a larger reduction in depressive score (four RCTs, SMD −0.76, 95% CI −1.14 to −0.39, p<0.0001). Heterogeneity among studies was insignificant

..Five trials focused on women with MDD. Of these, one assessed the effect of celecoxib added to sertraline, while the other four examined the antidepressive effect of omege-3 FA as monotherapy. Combining the five studies, no difference in score changes was found between groups (SMD −0.49, 95% CI −1.01 to 0.03, p=0.06), with moderate heterogeneity detected among studies

Conclusion
Our systematic review and meta-analysis suggests that anti-inflammatory agents exert an antidepressant effect in the treatment of MDD and were generally safe with rates of adverse effects similar to those of placebo. Adjunctive treatment shows a more remarkable effect with NSAIDs, omega-3 FAs, statins and minocyclines showing significant antidepressant effects for MDD.

Anti-inflammatory agents show promising effects for MDD. However, owing to the chronic course of MDD, quality of life and adverse effects should be further investigated in high-quality randomised clinical trials with long-term follow-up.

https://jnnp.bmj.com/content/early/2019/08/29/jnnp-2019-320912.full